The Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market will continue to increase as the number of ambulatory individuals seeking treatment for skin and skin structure infections rises

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are infections of the epidermis, dermis, and subcutaneous tissues that affect the skin and soft tissues. ABSSSI is defined by the US FDA as lesions having cellulitis/erysipelas, wound infections, and large cutaneous abscesses with a surface area of at least 75 cm2. ABSSSI is caused by pathogens such as Methicillin-sensitive Staphylococcus aureus (MSSA), Methicillin-resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, E. coli, Enterococcus faecalis, and Pseudomonas aeruginosa.The rising incidence of drug-resistant strains, particularly in Staphylococcus spp. and Enterococcus spp., makes this infection challenging to treat. The ABSSSI market is predicted to grow at a steady pace, thanks to an increasing number of patients suffering from these conditions and a significant number of pipeline treatments expected to be authorised during the forecast period.


Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Driver

Increased research and development activities by pharmaceutical and biopharmaceutical companies to produce new products and novel treatments are a major market driver for the Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market. For example, Cempra released positive results from a phase 3 trial of Fusidic acid for the treatment of ABSSSI in 2017. Melinta Therapeutics got FDA approval for Baxdela, a delafloxacin-based ABSSSI medication available in both intravenous and oral formulations, in the same year. Furthermore, in 2018, Fresenius Kabi received FDA approval for a new drug application of daptomycin, a lipopeptide antibacterial drug, in injectable form for complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria like Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactlae, and others.


However, rising occurrence of resistant strains of causative agents, stringent regulatory policies by government bodies, and patent expiration are projected to stifle ABSSSI market expansion.

The ABSSSI market will continue to increase as the number of ambulatory individuals seeking treatment for skin and skin structure infections rises. According to a 2015 report published in the PLoS One journal, hospital admissions for skin and skin structure infections climbed from 1.6 percent in 2005 to 2.0 percent in 2011. Furthermore, according to Decision Resource Group, paediatric patients accounted for 11% of the 2.7 million hospital admissions for ABSSSI in 2014. Manufacturers are aiming to expand their product line with pediatric-specific products in response to the growing number of paediatric patients.

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - Regional Analysis

North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa make up the global acute bacterial skin and skin structure infections (ABSSSI) market. North America dominates the ABSSSI market, which may be due to the regional market participants' vast number of pipeline products. However, because to rising awareness of ABSSSI treatment and manufacturers' regional development, Asia Pacific is likely to have rapid growth. In 2017, Basilea Pharmaceutics Ltd. signed an agreement with Shenzhen China Resources Gosun Pharmaceutical Co. to treat Methicillin-resistant Staphylococcus aureus infection in China, Hong Kong, and Macao by Basilea’s Zevtera.

Comments

Popular posts from this blog

Better awareness among women is driving the growth of the Bath Bombs Market

The global eSIM market was valued at USD 253.8 million in 2017 and is expected to reach USD 978.3 million by 2023

The rapid rise of the industrial tape business is one of the major reasons driving the growth of the gaffers tape market.